Dasatinib Accordpharma Den Europæiske Union - italiensk - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Livtencity Den Europæiske Union - italiensk - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - infezioni da cytomegalovirus - antivirali per uso sistemico - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antivirali.

Pyrukynd Den Europæiske Union - italiensk - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Vafseo Den Europæiske Union - italiensk - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - preparazioni antianemiche - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Dutrebis Den Europæiske Union - italiensk - EMA (European Medicines Agency)

dutrebis

merck sharp dohme limited - lamivudina, raltegravir di potassio - infezioni da hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis è indicato in combinazione con altri medicinali anti‑retroviral per il trattamento dell'infezione da virus dell'immunodeficienza umana (hiv‑1) in adulti, adolescenti e bambini dall'età di 6 anni e pesa almeno 30 kg senza presente o passato prova di resistenza virale agli agenti antivirali dell'insti (inibitore dell'integrasi strand transfer) e nrti (nucleoside reverse transcriptase inhibitor) (vedere paragrafi 4 classi. 2, 4. 4 e 5.

Vitekta Den Europæiske Union - italiensk - EMA (European Medicines Agency)

vitekta

gilead sciences international ltd - elvitegravir - infezioni da hiv - antivirali per uso sistemico - vitekta co-somministrato con un inibitore della proteasi potenziato con ritonavir e con altri agenti antiretrovirali, è indicato per il trattamento di umani-immunodeficienza-virus-1 (hiv-1) infezione in adulti che sono infettati con hiv-1 senza mutazioni note associate a resistenza a elvitegravir.

STELFONTA Italien - italiensk - Ministero della Salute

stelfonta

qbiotics netherlands b.v. - tigilanolo tiglato (tigilanol tiglate ebc-46) - tigilanolo tiglato (tigilanol tiglate ebc-46) - 1 mg - tigilanol tiglate

Sunlenca Den Europæiske Union - italiensk - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - infezioni da hiv - antivirali per uso sistemico - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 e 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 e 5.